How a Michigan Dermatologist Brings New Skin Treatments to Patients
Rapid change in inflammatory dermatology: what clinicians are seeing now
The pace of therapeutic innovation in inflammatory skin disease has picked up dramatically, and keeping up requires more than attending a few lectures — it means turning conference conversations into practical care plans back home.
At the 2026 American Academy of Dermatology (AAD) Annual Meeting, clinician-educator David Oberlin, MD, FAAD, who practices with Forefront Dermatology in Grand Rapids, Michigan, described how he sifts through the flood of new data, evaluates emerging medicines, and brings useful advances straight to patients (Source: American Academy of Dermatology 2026 Annual Meeting abstracts).
From a handful of options to a full toolbox
When Oberlin finished residency in 2019, some inflammatory diseases felt like clinical blind spots — conditions such as vitiligo and hidradenitis suppurativa had limited, often unsatisfying treatment options.
Since then, however, the treatment landscape has broadened considerably as drugmakers explore new molecular targets and repurpose existing mechanisms to treat skin disease.
That expansion shows up clearly on the AAD program, which included a wide range of sessions and posters on conditions from alopecia areata to chronic urticaria, highlighting both novel agents and new ways of thinking about disease biology (Source: American Academy of Dermatology 2026 Annual Meeting abstracts).
For clinicians and patients alike, the result is a shift from “we have few options” to “we have a toolbox” — more drugs, different mechanisms, and more opportunities to personalize care.
What the meeting really delivers: ideas that travel home
For Oberlin the AAD meeting isn’t an endpoint; it’s a launch point. He describes leaving conferences with his phone full of notes and a clear plan for how to test what he’s learned in real-world practice.
Those follow-up steps matter: conference talks spark new questions, hallway conversations refine clinical impressions, and industry discussions can point to emerging data worth watching. Putting those pieces together is what turns academic ideas into everyday treatment decisions.
Oberlin tries to convert that energy into better outcomes for patients right away. He aims to apply at least one insight from the meeting to his first clinic patients the next week — a mindset that makes the conference’s value practical, not just intellectual.
A practical framework for adopting new treatments
As a busy private-practice dermatologist who sees a large volume of patients each week, Oberlin has adopted a deliberate strategy for when and how to use new therapies: he considers himself an early but cautious adopter.
He filters every new option through three non-negotiable clinical priorities: safety, efficacy, and affordability. Those priorities shape whether he presents a drug as a realistic choice for a particular patient.
Oberlin also uses a familiar mental check: “Would I be comfortable prescribing this to a family member?” That personal standard helps him weigh theoretical benefits against practical risks and access barriers.
Ultimately, his approach is pragmatic: it’s better to have more tools in the toolbox, but the key question is matching the right tool to the right patient rather than reflexively chasing the newest agent.
Three clinic rules that guide new prescribing
Oberlin’s three clinic tenets — safe, effective, and affordable — are intentionally broad so they apply across disease states.
-
Safe: Does the safety profile fit this patient’s comorbidities and medication list?
-
Effective: Is there persuasive evidence of benefit in the condition and patient subgroup I’m treating?
-
Affordable: Can my patient access this treatment without unsustainable cost or delay?
Where oral options fit: a look at icotrokinra (Icotyde)
Among the therapies generating conversation at AAD, Oberlin singled out icotrokinra (Icotyde) as an oral agent with a potentially distinct clinical niche.
He described it as a promising oral therapy that may offer clinicians another practical option, especially for patients who prefer pills over injections or for whom other routes are impractical.
While conference buzz is encouraging, Oberlin emphasized the need to see how the drug performs in everyday clinical practice before changing prescribing habits broadly — a typical stance when early-phase or preliminary data generate enthusiasm (Source: American Academy of Dermatology 2026 Annual Meeting abstracts; Source: Icotyde developer press release).
Putting it all together: data, judgment, and patient-centered decisions
Oberlin’s process models how busy clinicians can incorporate the torrent of new information without losing clinical focus: absorb the science, apply a patient-centered filter, and prepare to act the next business day if the evidence and circumstances align.
That combination of intellectual curiosity and grounded judgment helps convert conference insights into improved care, one patient at a time.
For practicing dermatologists, the strategy is simple in concept though disciplined in practice: learn broadly, evaluate carefully, and then choose the right treatment for each individual.
Sources
- American Academy of Dermatology (AAD) 2026 Annual Meeting abstracts and program materials (Source: American Academy of Dermatology 2026 Annual Meeting abstracts).
- Forefront Dermatology physician profile for David Oberlin, MD, FAAD (Source: Forefront Dermatology physician directory).
- Henry Ford Health System residency records/profile for dermatology graduates (Source: Henry Ford Health System residency program information).
- Presentation and developer materials on icotrokinra (Icotyde) highlighted at AAD 2026 (Source: Icotyde developer press release; AAD 2026 abstract).